Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches

Infect Dis Clin North Am. 2016 Jun;30(2):491-507. doi: 10.1016/j.idc.2016.02.009.

Abstract

This article reviews recent clinical evidence for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Vancomycin remains the initial antibiotic of choice for the treatment of patients with MRSA bacteremia and endocarditis due to isolates with vancomycin minimum inhibitory concentration ≤2 μg/mL, whereas daptomycin is an effective alternative, and ceftaroline seems promising. Treatment options for persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or vancomycin-resistant strains include daptomycin, ceftaroline, and combination therapies. There is a critical need for high-level evidence from clinical trials to allow optimally informed decisions in the treatment of MRSA bacteremia and endocarditis.

Keywords: Bacteremia; Ceftaroline; Daptomycin; Endocarditis; MRSA; Methicillin; Staphylococcus aureus; Vancomycin.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents* / administration & dosage
  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Bacteremia* / drug therapy
  • Bacteremia* / microbiology
  • Ceftaroline
  • Cephalosporins
  • Daptomycin
  • Humans
  • Methicillin-Resistant Staphylococcus aureus*
  • Microbial Sensitivity Tests
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / microbiology
  • Vancomycin

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Vancomycin
  • Daptomycin